Eton Pharmaceuticals annual ebitda
2018
2019
2020
2021
2022
2023
2024
2025
Eton Pharmaceuticals EBITDA Growth & History (ETON)
Eton Pharmaceuticals's calculated EBITDA was $3.2M for fiscal 2025.
View full Eton Pharmaceuticals company overviewEton Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.2M | $4.7M | — |
| 2024 | 2024-12-31 | −$1.5M | −$1.2M | — |
| 2023 | 2023-12-31 | −$291,000 | $7.9M | — |
| 2022 | 2022-12-31 | −$8.2M | −$6.9M | — |
| 2021 | 2021-12-31 | −$1.3M | $25.4M | — |
| 2020 | 2020-12-31 | −$26.8M | −$8.4M | — |
| 2019 | 2019-12-31 | −$18.3M | −$8.1M | — |
| 2018 | 2018-12-31 | −$10.3M | — | — |
Eton Pharmaceuticals quarterly ebitda
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.2M | $14.7M | — |
| Q1 2026 | 2026-03-31 | $3.5M | $3.0M | +552.85% |
| Q4 2025 | 2025-12-31 | $3.5M | $2.5M | +253.76% |
| Q3 2025 | 2025-09-30 | −$354,000 | −$1.1M | — |
| Q2 2025 | 2025-06-30 | −$470,000 | $2.2M | — |
| Q1 2025 | 2025-03-31 | $543,000 | $1.1M | — |
| Q4 2024 | 2024-12-31 | $984,000 | $2.7M | — |
| Q3 2024 | 2024-09-30 | $787,000 | $1.1M | — |
| Q2 2024 | 2024-06-30 | −$2.7M | −$6.7M | — |
| Q1 2024 | 2024-03-31 | −$566,000 | $1.8M | — |
| Q4 2023 | 2023-12-31 | −$1.7M | −$2.7M | — |
| Q3 2023 | 2023-09-30 | −$357,000 | $2.5M | — |
| Q2 2023 | 2023-06-30 | $4.1M | $5.4M | — |
| Q1 2023 | 2023-03-31 | −$2.3M | $2.7M | — |
| Q4 2022 | 2022-12-31 | $1.1M | −$262,000 | −19.60% |
| Q3 2022 | 2022-09-30 | −$2.9M | $2.9M | — |
| Q2 2022 | 2022-06-30 | −$1.3M | $979,000 | — |
| Q1 2022 | 2022-03-31 | −$5.1M | −$10.5M | — |
| Q4 2021 | 2021-12-31 | $1.3M | $8.9M | — |
| Q3 2021 | 2021-09-30 | −$5.8M | $285,000 | — |
| Q2 2021 | 2021-06-30 | −$2.3M | $2.1M | — |
| Q1 2021 | 2021-03-31 | $5.4M | $14.2M | — |
| Q4 2020 | 2020-12-31 | −$7.6M | −$4.9M | — |
| Q3 2020 | 2020-09-30 | −$6.1M | −$1.2M | — |
| Q2 2020 | 2020-06-30 | −$4.4M | −$1.1M | — |
| Q1 2020 | 2020-03-31 | −$8.7M | −$1.2M | — |
| Q4 2019 | 2019-12-31 | −$2.7M | −$409,000 | — |
| Q3 2019 | 2019-09-30 | −$4.9M | −$2.6M | — |
| Q2 2019 | 2019-06-30 | −$3.2M | −$542,000 | — |
| Q1 2019 | 2019-03-31 | −$7.5M | −$4.5M | — |
| Q4 2018 | 2018-12-31 | −$2.3M | — | — |
| Q3 2018 · Sep 30 | 2018-09-30 | −$2.4M | — | — |
| Q2 2018 | 2018-06-30 | −$2.7M | — | — |
| Q1 2018 | 2018-03-31 | −$3.0M | — | — |
Eton Pharmaceuticals ebitda trends
Over the last five fiscal years, Eton Pharmaceuticals's ebitda increased from −$26.8M to $3.2M, a change of $30.0M. The latest reported quarter, Q2 2026, shows $14.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eton Pharmaceuticals source filings ↗Community posts
Eton begins U.S. commercialization of IMPAVIDO under exclusive rights
Eton Pharmaceuticals ($ETON) launched IMPAVIDO capsules through its U.S. rare-disease commercial organization after obtaining exclusive domestic commercialization rights. The medicine contains miltefosine and treats specified forms of leish ...
